Kornimate/medical-research-clean huggingface dataset:
effectiveness of botulinum toxin injection in the tennis elbow treatment

Conditions: Tennis Elbow

Summary: some studies valued the effectiveness of botulinum toxin. results are contradictory and we need more studies. the purpose of the study is to compare the effectiveness of botulinum toxin injection with placebo in the treatment of tennis elbow unrelieved by usual medical care performed during 6 months. method : it is a double blind randomized controlled trial. principal criteria of assessment is pain intensity three months after injection.

* principal objective : the first aim of the study is to value the effectiveness of botulinum toxin injection in the treatment of tennis elbow unrelieved by usual medical care performed during 6 months.. * secondary objective : the second aim of this study is to document the tennis elbow history by a one year following after initial injection * study design : it is a double blind randomized controlled trial. principal criteria of assessment is pain intensity three months after injection. * inclusion criteria : tennis elbow during more than 6 months ; signature of consent * exclusion criteria : non inclusion criteria : less than 18 years old ; osteoarthritis elbow, referred cervical pain, fibromyalgia, pregnancy, myasthenia, polymyositis, sla, anticoagulant treatment, aminosides ; diabetes, alcoholism * study plan: randomized parallel groups * number of subjects : 60

Eligibility criteria:
inclusion criteria: * tennis elbow during more than 6 months * signature of consent exclusion criteria: * less than 18 years old * osteoarthritis elbow * referred cervical pain * fibromyalgia * pregnancy * myasthenia * polymyositis * sla * anticoagulant treatment * aminosides * diabetes * alcoholism * previous botulinum toxin a injections

Keywords: lateral epicondylitis, tennis elbow, treatment
use of topical tranexamic acid and bacitracin in dialysis patients

Conditions: Arteriovenous Fistula

Summary: this study will investigate how the use of tranexamic acid and bacitracin applied to the bleeding site after the hemodialysis fistula needle is removed will affect time to clot and infection rate

visit 1 - initial application: * a patient candidate identified by the pi who meets all of the inclusion criteria and none of the exclusion criteria will be consented for the study. * the medical history will be collected from the subject. * the subject will receive routine hemodialysis * directly after the completion of hemodialysis, the following study drug application steps will occur: 1. site 1 initial compression: apply fixed amount of tranexamic acid and bacitracin 5% or 25% to gauze and compress for 3 minutes to needle site 1. 2. site 2 initial compression: apply fixed amount of tranexamic acid and bacitracin 5% or 25% to gauze and compress for 3 minutes to needle site 2. 3. second compression per site: if bleeding has not stopped, repeat application with new gauze and same amount of ointment to each respective site and compress for 5 minutes more at each site. 4. third compression per site: if after the second application and compression the bleeding persists repeat both application and compression for another 5 minutes (total time would be 13 minutes at this step). 5. test failure: if after the third application to each needle site there is still bleeding, the testing would be considered a failure and routine procedures should be utilized to stop the bleeding. * any adverse events will be collected. visit 2 - follow-up: • the 1 week follow up visit will be performed to review study drug application site and to collect any adverse events reported by subject the clotting time will be compared to the clotting time at a different dialysis session in which no treatment will be used

Eligibility criteria:
inclusion criteria: * dialysis patients with fistulas (native arterio-venous) exclusion criteria: * previous sensitivity to or adverse reaction to tranexamic acid or bacitracin. * active infection. * stenosis of fistula.

Keywords: hemodialysis fistula clotting tranexamic acid bacitracin
requirements and functional schedule as a part of painrehabilitation.

Conditions: Chronic Pain

Summary: requirements and functional schedule also calen demand ability protocol (dap) is an intervention that has been tested and found useful in occupational health service. the intervention aims to strengthen the collaboration between health care, employers and employee. the intervention is based on a structured interview about the employers demands at work. this intervention (dap) will in the present study be evaluated in pain rehabilitation both qualitatively and quantitatively.

description of the intervention: demand and ability protocol demand and ability protocol (dap) is an intervention linked to the international classification of functioning, disability and health, and is based on the dutch functional ability list and knowledge about disability in working life (brouwer et al, 2002). the intervention has been further developed and modified in norway and is primarily used in occupational health care services for collaboration between an employee and his or her immediate manager (engbers \& furuland, 2006). the intervention consists of a structured conversation between the patient and his immediate manager under the guidance of licensed medical staff (in this case reko) with knowledge of the requirements of the patient's work and his/her current functional ability. the intervention takes about 90 minutes excluding preparation time for reko. dap consider the following domains; 1) mental and cognitive ability, 2) basic skills and social ability, 3) tolerance for physical conditions, 4) ability to work dynamically, 5) ability to work statically and 6) to be able to work certain times. based on the above domains, a structured review is made of the balance between requirements and function in current work in order to identify possible adaptations and measures at the workplace. during the intervention, the work requirements and the patient's function/ability are identified on a three-point scale and in domains where the rating of requirements and function/ability does not match, there is thus an imbalance, and here adjustments or changed tasks may be relevant to consider increasing work ability and reducing sick leave. the intervention concludes with a summary of the situation and joint development of appropriate measures/adaptations to promote the patient's rtw. this is documented on a form, which is signed by both the patient and the manage

Eligibility criteria:
inclusion criteria: chronic pain, has an employment exclusion criteria: no longer than 6 month of total sick-leave
antiretroviral treatment outcomes in hiv-hbv co-infected patients in southern africa

Conditions: Hepatitis B Virus; HIV; Antiretroviral Therapy; Africa; Liver Fibrosis; Alcohol Use Disorder

Summary: this is a prospective hiv cohort that aims to establish causes of liver disease among hiv-infected individuals in zambia, including viral hepatitis and alcohol.

the study will take place during routinely scheduled art visits as per ministry of health guidelines. routinely collected programmatic data will be used to assess general hiv outcomes (cd4 response, loss to follow-up, death) as well as collecting study specific data (hepatitis testing, questionnaire regarding risk factors for hepatitis/liver disease, and non-invasive liver scan) to address other aims. the study will be implemented at two sites in southern africa (zambia and mozambique) with a total enrollment across all sites of 1,900 participants. the zambia site will only enroll 900.

Eligibility criteria:
inclusion criteria: * hiv-infected * male or female aged ≥18 years * art naïve * art eligible as defined by zambian or who treatment guidelines * initiating an art regimen including at least 3 drugs at one of the study sites. * willing to provide signed informed consent and be followed at the clinical site. exclusion criteria: * patients who are not planning to remain in the catchment area from which they were recruited for the duration of the study

Keywords: antiretroviral therapy hepatitis c virus
greater occipital nerve blockade and sphenopalatine ganglion blockade in patients with episodic migraine

Conditions: Greater Occipital Nerve Block; Sphenopalatine Ganglion Block; Episodic Migraine

Summary: this study compares the effectiveness of greater occipital nerve blockade and sphenopalatine ganglion blockade in reducing headache intensity, duration, frequency, and disability in patients with episodic migraine.

migraine is a chronic neurological disorder characterized by recurrent headaches, affecting millions globally. peripheral nerve blocks such as greater occipital nerve (gon) and sphenopalatine ganglion (spg) blockade have emerged as promising non-pharmacologic treatments.

Eligibility criteria:
inclusion criteria: * adults aged 18-65 years. * both sexes. * diagnosed with episodic migraine per the international classification of headache disorders, 3rd edition (ichd-3). * failure to achieve adequate relief with at least one prophylactic migraine treatment. exclusion criteria: * chronic migraine (≥15 headache days per month). * history of nerve blocks within the last 6 months. * known allergy to anesthetic agents. * pregnancy or lactation. * active psychiatric conditions affecting compliance.
comparative effectiveness of cryoablation versus steroid and lidocaine alone for treatment of morton's neuroma

Conditions: Morton Neuroma

Summary: morton's neuroma is a benign thickening involving the plantar interdigital nerve, most common in middle aged women. morton's neuroma is one of the most frequent diagnoses seen in the investigators podiatry clinic and is difficult to treat. these lesions cause a burning or shooting pain that can radiate to the toes, or an aching pain in the ball of the foot. the pain is exacerbated with activity and certain footwear greatly limits activity in the involved patient population. morton's neuroma is first treated conservatively with orthotics. patients may require further interventions such as steroid injections. the literature reports only a 30% long term resolution of pain with the steroid. surgical resection has a reported 51-85% success rate with 14-21% rate of complication; recurrent pain, numbness/loss of sensation, and subsequent stump neuromas. cryoablation is well known to be efficacious for neuropathic pain and has recently been shown in two small studies to be safe and efficacious for treatment of morton's neuroma. the investigators study will compare outcomes of cryoablation to corticosteroid injection in short- and long-term for treatment of morton's neuroma that have failed conservative therapy.


Eligibility criteria:
inclusion criteria: * age \>18 years * able to consent and complete questionnaires * failure of a four-week trial of conservative therapy (includes orthotics, appropriate footwear, and/or metatarsal pads) * x-ray and ultrasound excluding other pathology and confirming the presence and location of a morton's neuroma exclusion criteria: * inability to follow-up or to comply with the follow-up protocol * contraindication to cryoablation and/or lidocaine/steroid injection * other pathology which could account for symptoms identified on imaging studies * unwillingness to be randomized
a study evaluating safety and pharmacokinetics of abbv-221 in subjects with advanced solid tumor types likely to exhibit elevated levels of epidermal growth factor receptor

Conditions: Head and Neck Squamous Cell Carcinoma; Non-small Cell Lung Cancer; Triple Negative Breast Cancer; Colorectal Carcinoma; Glioblastoma Multiforme

Summary: this is an open-label, phase i, dose escalation study to determine the recommended phase 2 dose, maximum tolerated dose, and evaluate the safety and pharmacokinetic profile of abbv-221 in participants with advanced solid tumors likely to exhibit elevated levels of epidermal growth factor receptor (egfr).


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status 0 or 2. * has a solid tumor likely to exhibit elevated levels of egfr (e.g. head and neck squamous cell carcinoma, non-small cell lung cancer, triple negative breast cancer ,colorectal carcinoma and glioblastoma multiforme). * has an archived, diagnostic tumor tissue available for analysis. * has adequate hematologic, renal, cardiac and hepatic function. * expanded safety cohort participants must have confirmed metastatic lung cancer and progressed after receiving prior platinum-containing chemotherapy. exclusion criteria: * previously received an egfr-directed monoclonal antibody within the past 4 weeks. * has unresolved, clinically significant toxicities from prior anti-cancer therapy defined as \> grade 1 on common terminology criteria for adverse events. * history of major immunologic reaction to any igg containing agent. * any medical condition which in the opinion of the investigator places the participant at an unacceptably high risk for toxicities.

Keywords: oncology cancer solid tumor types likely to exhibit elevated levels of epidermal growth factor receptor solid tumors
perımenopausal women's attıtudes towards menopause and spırıtual well-beıng

Conditions: Menopause; Activity, Motor; Attitude

Summary: menopause; cessation of menstruation due to cessation of follicular activity is the transition from the reproductive period to non-reproductive life. considering that the average life expectancy is increasing, women spend most of their lives in the menopausal period. women who have a positive attitude towards menopause have a positive body image, experience less depressive experiences, and the severity of menopause symptoms decreases. it has also been assumed that spiritual well-being is effective in reducing the severity of menopause symptoms and anxiety, supporting positive body image, and coping with losses. baduanjin exercise is a type of body mind exercise. it increases the production of life energy and distributes it to different aspects of the body. it is thought that the baduanjin body-mind exercise to be applied to perimenopausal women will have positive effects on the spiritual well-being of menopausal women and their attitudes towards menopause. thus, it is expected that women's transition and adaptation to the menopause process will be easier.

this study will be carried out as a pre-test - post-test randomized controlled experimental study. the population of the research consists of female patients between the ages of 45-55 who are registered to a family health center located in a provincial center in the north of turkey. women who are in the perimenopausal period and meet the inclusion criteria according to the staging of reproductive aging in women (straw) criteria will be included in the study. the random.org program will be used to unbiasedly assign 60 women who meet the research criteria to the experimental and control groups. the menopause adaptation program will be applied to the intervention regimen. this program, which will be applied to the experimental group, was prepared based on the meleisin transition theory. since women's menopause is a transition process, the transition theory was preferred. within the scope of the program, the experimental group will be given online menopause health education for the first 6 weeks and baduanjin exercise will be taught. for the next 8 weeks, individuals will be asked to practice the baduanjin exercise 3 times a week. online consultation will be provided during this period. the study will be completed in 14 weeks in total. no intervention will be applied to the control group. the study will be terminated after the post-test data is collected. data will be collected using the introductory information form, the attitudes towards menopause scale (mitö, spirituality index of well-being scale).

Eligibility criteria:
inclusion criteria: * being in the perimenopausal period * being between the ages of 40-55 * having entered menopause naturally * volunteering to participate in research exclusion criteria: * having a physical problem that prevents exercise * being on hormone therapy * not having a menstrual period for more than 8 months * not using a smartphone

Keywords: perimenopause baduanjin menopause attitude
an open-label study of the long-term safety of dapoxetine hcl in the treatment of rapid ejaculation

Conditions: Ejaculation; Erectile Dysfunction; Sexual Dysfunction

Summary: the purpose of this study is to evaluate the long-term safety of dapoxetine in men with rapid ejaculation.

this is a multicenter, open-label (patients and investigators will know the name of the drug that they are receiving) study to evaluate the long-term safety and efficacy of dapoxetine therapy in adult men with premature (rapid) ejaculation (pe) who participated in 1 of 2 previous studies of dapoxetine ( alza protocol c-2002-012 or c-2002-013). the length of the study will be up to 9 months. during the study, patients will be monitored for safety by review of adverse events and findings from routine laboratory tests, vital signs measurements, electrocardiograms (ecgs), and physical examinations. oral tablets of dapoxetine (30 mg or 60 mg) will be self-administered by patients once daily, as needed, for up to 9 months. no more than 1 dose within a 24-hour period should be taken. if the 60 mg dose of dapoxetine is not well tolerated, the dose may be decreased to 30 mg dapoxetine for the remainder of the study. patients who do not tolerate the 30 mg dose of dapoxetine should be discontinued from the study.

Eligibility criteria:
inclusion criteria: * enrollment within 30 days of completion of 1 of the 2 phase 3 controlled studies (alza study c-2002-012 or study c-2002-013) * in the opinion of the investigator, the patient could safely continue the use of dapoxetine treatment * had a systolic blood pressure of \<=180 mm hg and a diastolic blood pressure \<=100 mm hg * agreement by patient's sexual partner (if of childbearing potential) to ensure use of a medically acceptable method of contraception for the duration of the study exclusion criteria: * currently taking any any protocol-defined prohibited medications * reported a diagnosis of any sexually transmitted disease, had a new allergy or hypersensitivity to dapoxetine or other selective serotonin reuptake inhibitors * in the opinion of the investigator is incapable of following the study schedule for any reason

Keywords: dapoxetine, orgasmic disorder premature ejaculation sexual dysfunction sexual intercourse ejaculation erectile dysfunction
fertility changes due to cancer: an investigation of meaning, psychological distress, and psychologi

Conditions: Breast Cancer Female

Summary: establish the relationship between meaning and psychological distress in young women with breast cancer who experienced reproductive concerns due to cancer diagnosis and treatment and their partners.

this research will focus on identifying avenues for improving the quality of life of young women with breast cancer who endorse reproductive concerns due to cancer diagnosis and treatment, as there is an increased likelihood of distress and decreased likelihood of receiving information and appropriate psychological care. existential distress appears to play a role in coping with infertility due to cancer (8) and thus the relationship between this distress and the other types of reproductive concerns warrants further exploration. the proposed project will use a mixed methods design to characterize the relationship between sense of meaning and purpose and psychological distress and assess psychosocial support needs of these young women. it will also assess the experience of the identified partners of these young women.

Eligibility criteria:
participant inclusion criteria: * provision to complete the consent form. * stated willingness to comply with all study procedures and be available for the duration of the study. * able to confirm they have a valid and private email account and access to the internet. * patients age 18 to 45 with a diagnosis of breast cancer. patients will endorse that they experience reproductive concerns due to cancer as assessed by a single screening item. * fluent and literate in english. partner participant inclusion criteria: * provision to complete the consent form. * stated willingness to comply with all study procedures and be available for the duration of the study. * able to confirm they have a valid and private email account and access to the internet. * be the identified supportive partner of a study participant. * fluent and literate in english. exclusion criteria: * an individual who fails to meet any of the inclusion criteria will be excluded from participation in this study.
a pilot study of diffusion mri in the assessment of pancreatic tumor response

Conditions: Pancreatic Cancer

Summary: patients with pancreatic cancer are treated with combinations of surgery, radiation therapy and chemotherapy, depending on the location of the cancer and other individual patient health factors. the goals of therapy are to reduce or eliminate the cancer cells, but without serious damage to normal cells. investigators at the university of michigan are conducting a research project, to see if treatment effects on an individual patient's cancer cells can be detected early by new imaging tests in patients with resectable pancreatic cancer undergoing neoadjuvant chemoradiotherapy.

patients with pancreatic cancer are treated with combinations of surgery, radiation therapy and chemotherapy, depending on the location of the cancer and other individual patient health factors. the goals of therapy are to reduce or eliminate the cancer cells, but without serious damage to normal cells.each patient is unique in terms of the cancer type and location and its sensitivity to treatments. investigators at the university of michigan are conducting a research project to see if treatment effects on an individual patient's cancer cells can be detected early by new imaging tests in patients with resectable pancreatic cancer undergoing neoadjuvant chemoradiotherapy. each patient is unique in terms of the cancer type and location and its sensitivity to treatments.

Eligibility criteria:
inclusion criteria: * patients with histologic or cytologic proof of pancreatic cancer, for whom the treatment plan, at the time of enrollment, is neoadjuvant chemoradiotherapy followed by surgical resection. * patients must be \>18 years old. * patients cannot weight over 300 pounds, the weight limit of the mri table. * patients must have adequate renal function (estimated glomerular filtration rate \> 60 ml/min/m2), to minimize the small risk of nephrogenic systemic sclerosis associated with gadolinium injection. * patients must sign an informed consent indicating that they are aware of the investigational nature of this study, in keeping with the policies of um hospital. exclusion criteria: * patients must have no previous radiation to the abdomen. * patients who are pregnant or lactating are excluded.